Crossmark

Commentary on “real world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: a meta-analysis of clinical studies”

Crossref DOI link: https://doi.org/10.1186/s40360-025-00923-1

Published Online: 2025-04-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Namdar, Ali Beheshti

Keikha, Masoud
License Information

Text and Data Mining valid from 2025-04-11

Version of Record valid from 2025-04-11
More Information

Article History

Received: 23 March 2025

Accepted: 9 April 2025

First Online: 11 April 2025

Declarations

:

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below